医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd & Zhangjiajie Tourism Group Co. Ltd Entered a Strategic Cooperation Agreement

2016年01月01日 AM08:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

As at January 1, 2016, Zhangjiajie (China) Jinchi Giant Salamander Biological Technology Co. Ltd (“Zhangjiajie Jinchi”), a wholly-owned subsidiary of Jinchi Biotech Ltd ( “Jinchi Biotech”)(NSX:JCB), entered a strategic cooperation agreement (the “Strategic Cooperation Agreement”) with Zhangjiajie Tourism Group Co. Ltd (“Zhangjiajie Tourism Group”, stock code:000430).

Zhangjiajie Jinchi and Zhangjiajie Tourism Group will cooperate on marketing, promoting, advertising and training, and share advertisement resources and launch a new exquisite tourism route: Yangjiajie, Baofeng Lake and Zhangjiajie Giant Salamander Science Museum.

Zhangjiajie Tourism Group is a state-owned holding company listed on the Shenzhen Stock Exchange with tourism resources development, tourism infrastructure construction, high-tech development in tourism industry, and security investment consultancy services as its main business. In 2014, Zhangjiajie Tourism Group achieved annual operating income about AUD$ 104,350,000 (RMB 484,009,400) and received nearly 5 million tourists, among which Yangjiajie and Baofeng Lake attracted 339,300 and 562,400 tourists respectively.

The Strategic Cooperation Agreement, which is mainly focused on Zhangjiajie tourism industry, can help promote Zhangjiajie Giant Salamander Science Museum to worldwide tourists and enhance brand effect and advertising effect. This agreement is expected to bring Zhangjiajie Giant Salamander Science Museum more than 200,000 tourists, which may greatly increase ticket proceeds and product sales revenue in 2016.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151231005058/en/

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • フェリングが微生物叢ベースのライブバイオ治療薬RBX2660に関する米国FDA諮問委員会会議の開催を発表
  • 辉凌宣布美国FDA咨询委员会就公司基于微生物群的在研活体生物疗法RBX2660召开会议
  • Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time
  • Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors
  • 2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L. Brown Outlines Search for Victims of 1921 Tulsa Race Massacre